Reference tables
Peptide reference tables
Four cross-compound tables generated from the same catalog that drives every compound page on this site. Each answers one question across all 105 compounds at once, rather than one compound at a time.
Regulatory status
FDA-approved peptides
Every catalog compound with a labeled indication from a national regulator, with the brand names the site's compound pages state.
20 of 105 compounds
Anti-doping
WADA-prohibited peptides
Compounds this site documents as named or captured on the WADA Prohibited List, grouped by the category code each compound page cites.
38 compounds across 11 categories
Pharmacokinetics
Peptide half-lives
Published elimination half-lives, shortest to longest, with the administration route noted wherever the source reports one.
18 of 105 compounds
Evidence
Peptide evidence tiers
All 105 catalog compounds sorted into four tiers by the strongest evidence that exists for them, from approved medicines to compounds with no independent literature.
105 compounds, 4 tiers
How these tables are built
Every row on these four pages is generated at build time from the catalog record for a compound, and from the compound page’s own text where the fact in question lives in prose rather than in a field. Nothing is typed twice. If a compound gains a half-life value or a regulatory approval, the table changes on the next build without anyone editing it — and if a value was never verified, the cell is empty rather than filled with a guess.
That last point is the one worth dwelling on. Most peptide reference material on the web fills every cell, because an empty cell looks like a gap in the work. Here an empty cell is the finding: it means no drug label and no published pharmacokinetic study reported a value that could be checked. Half-life is documented for 18 of 105 catalog compounds, and the remaining 87 are absent from that table entirely rather than padded with numbers copied from vendor marketing.
The four tables cut across each other in useful ways. A compound can be an approved medicine and prohibited in sport at the same time — recombinant growth hormone and erythropoietin both are. A compound can be prohibited in sport while sitting in the lowest evidence tier, which is the usual shape of the experimental peptide market. And a compound can have a long half-life and almost no human data, which is precisely the combination that makes dosing intervals guesswork. Read side by side, the tables describe a market where regulatory status, competitive eligibility and evidence quality are three separate axes that people routinely collapse into one.
These pages are educational reference material. They describe what regulators, anti-doping authorities and published studies have said; they do not recommend, endorse, or instruct anyone to use anything. See the medical disclaimer and editorial policy for how sourcing and review work on this site, and the full catalog for the compound pages these tables summarise. Where two compounds are close enough that the tables invite a direct question — approved against unapproved, weekly against daily — the side-by-side comparisons answer it in prose rather than in cells.